mirabegron
mirabegron is listed in the FDA National Drug Code directory with 15 NDC codes, marketed under brand names including Mirabgeorn, MIRABEGRON, Mirabegron. Available dosage forms: tablet, film coated, extended release, granule, for suspension, extended release, powder.
Drug details
- Generic Name
- mirabegron
- Brand Names
- Mirabgeorn, MIRABEGRON, Mirabegron, Myrbetriq
- Application Number
- ANDA217989
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
- NDC Codes
- 15
- Dosage Forms
- TABLET, FILM COATED, EXTENDED RELEASE, GRANULE, FOR SUSPENSION, EXTENDED RELEASE, POWDER
- Routes
- ORAL
- Active Ingredients
- MIRABEGRON
Indications and Usage
1 INDICATIONS AND USAGE Mirabegron extended-release tablets are a beta-3 adrenergic agonist indicated for the treatment of: Overactive bladder (OAB) in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency. ( 1.1 ) Neurogenic detrusor overactivity (NDO) in pediatric patients aged 3 years and older and weighing 35 kg or more. ( 1.2 ) 1.1 Adult Overactive Bladder (OAB) Mirabegron Monotherapy Mirabegron extended-release tablets are indicated for the treatment of OAB in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency. 1.2 Pediatric Neurogenic Detrusor Overactivity (NDO) Mirabegron extended-release tablets are indicated for the treatment of NDO in pediatric patients aged 3 years and older and weighing 35 kg or more.